Jack is a Professor in the Department of Cellular and Molecular Pharmacology at the University of California, San Francisco. His research focuses on the design and discovery of chemical tools to study cellular processes relevant to human disease. Areas of interest include the structure-based design of covalent inhibitors and chemoproteomic probes, as well as mechanistic studies of biologically active natural products. Work in Jack’s lab has led to the development of rilzabrutinib, a reversible covalent BTK inhibitor in clinical trials for immune thrombocytopenia. He is a cofounder of Principia BioPharma, Global Blood Therapeutics, Kezar Life Sciences and Cedilla Therapeutics, and a scientific advisor to Iambic Therapeutics.